Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oragenics, Inc. (OGEN)
USD0.56
-0.01 (-1.03%)
US AMEX Healthcare Biotechnology
Address
4902 Eisenhower Boulevard 33634
Tampa, FL, US
Tampa, FL, US
CEO
Janet Huffman
Website
oragenics.com
IPO
2004-02-25
CIK 1174940 ISIN US6840236094
Description
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.56
-0.01 (-1.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
55.2K
Beta
1.26
Float Shares
4.24M
Free Float %
97.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.60% | -11.98% | -7.53% | -13.55% | -51.93% | -28.80% | -89.67% | -99.39% | -99.95% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Hold
Price Targets & DCF
Current price
0.56
DCF (Unlevered)
1.95
+248.1%
DCF (Levered)
1.93
+245.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-10 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-44.55
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-185.0% Q1'26: +85.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-8,587.3% Q1'26: -6,827.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-67.4% ★ Q1'26: +608.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.18M
est: 2.41M (-51.3%)
|
—
est: 10.86M (-100.0%)
|
—
est: 11.97M (-100.0%)
|
—
est: 100.0K (-100.0%)
|
—
est: 38.0K (-100.0%)
|
—
|
—
|
—
— – —
|
—
— – —
|
2.25M
2.25M – 2.25M
|
45.00M
45.00M – 45.00M
+1,900.0% YoY
|
| EBITDA |
-11.56M
|
-8.42M
|
-6.45M
|
-14.23M
|
-20.60M
|
-10.54M
|
-9.36M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-11.76M
|
-8.49M
|
-6.72M
|
-14.27M
|
-20.63M
|
-10.54M
|
-9.36M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-11.71M
est: -1.47B (+99.2%)
|
-7.01M
est: -21.46B (+100.0%)
|
-6.73M
est: -27.42B (+100.0%)
|
-14.29M
est: -1.91B (+99.3%)
|
-20.66M
est: -2.15B (+99.0%)
|
-10.57M
est: -5.03M (-110.0%)
|
-9.84M
est: -1.64M (-500.4%)
|
-1.49M
-1.49M – -1.49M
+9.2% YoY
|
-906.0K
-906.0K – -906.0K
+39.1% YoY
|
-841.3K
-841.3K – -841.3K
+7.1% YoY
|
625.6K
625.6K – 625.6K
+174.4% YoY
|
| SGA |
3.54M
|
3.79M
|
3.18M
|
4.48M
|
5.45M
|
6.44M
|
6.97B
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-192.00
est: -222.00 (+13.5%)
|
-94.35
est: -3,240.00 (+97.1%)
|
-81.99
est: -4,140.00 (+98.0%)
|
-7.11
est: -288.00 (+97.5%)
|
-9.18
est: -324.00 (+97.2%)
|
-1.60
est: -0.76 (-110.5%)
|
-4.56
est: -0.76 (-500.0%)
|
-0.69
-0.69 – -0.69
+9.2% YoY
|
-0.42
-0.42 – -0.42
+39.1% YoY
|
-0.39
-0.39 – -0.39
+7.1% YoY
|
0.29
0.29 – 0.29
+174.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-12.87M
OE per share TTM
-6.95
Owner's Yield
-501.46%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
213.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Joseph Hernandez | 9.20M | 16.60% | 9.20M | — | 9.20M | — | IN | Citizenship or Place of Organization | 2020-05-15 | ↗ |
| 2 | Randal J. Kirk | 4.39M | 26.50% | — | — | — | 10.00 | IN | United States | 2012-06-12 | ↗ |
| 3 | GP LLC | 4.00M | 8.70% | — | 4.00M | — | 4.00M | HC, OO | Texas | 2019-03-29 | ↗ |
| 4 | Inc. | 4.00M | 8.70% | — | 4.00M | — | 4.00M | CO | Texas | 2019-03-29 | ↗ |
| 5 | Kassam | 4.00M | 8.70% | — | 4.00M | — | 4.00M | IN | Texas | 2019-03-29 | ↗ |
| 6 | Nathoo | 4.00M | 8.70% | — | 4.00M | — | 4.00M | IN | Texas | 2019-03-29 | ↗ |
| 7 | Winson | 4.00M | 8.70% | — | 4.00M | — | 4.00M | HC, IN | Texas | 2019-03-29 | ↗ |
| 8 | Abigail P. Johnson | 2.80M | 7.73% | — | — | 2.80M | — | IN | Delaware | 2015-02-13 | ↗ |
| 9 | Edward C. Johnson 3d | 2.80M | 7.73% | — | — | 2.80M | — | IN | Delaware | 2015-02-13 | ↗ |
| 10 | FMR LLC | 2.80M | 7.73% | — | — | 2.80M | — | HC | Delaware | 2015-02-13 | ↗ |
| 11 | Select Biotechnology Portfolio | 2.55M | 7.04% | 2.55M | — | — | — | IV | Delaware | 2015-02-13 | ↗ |
| 12 | CVI Investments, Inc. | 2.42M | 4.90% | — | 2.42M | — | 2.42M | CO | Cayman Islands | 2020-02-10 | ↗ |
| 13 | Heights Capital Management, Inc. | 2.42M | 4.90% | — | 2.42M | — | 2.42M | CO | Delaware | 2020-02-10 | ↗ |
| 14 | Management LP | 2.42M | 4.90% | — | 2.42M | — | 2.42M | IA, PN | United States | 2020-02-14 | ↗ |
| 15 | Altium Growth GP, LLC | 2.00M | 9.90% | — | 2.00M | — | — | PN | Delaware, United States of America | 2018-07-23 | ↗ |
| 16 | Empery Asset Management, LP | 1.75M | 4.99% | — | 1.75M | — | — | PN | Delaware | 2019-01-17 | ↗ |
| 17 | Martin D. Hoe | 1.75M | 4.99% | — | 1.75M | — | — | IN | United States | 2019-01-17 | ↗ |
| 18 | Ryan M. Lane | 1.75M | 4.99% | — | 1.75M | — | — | IN | United States | 2019-01-17 | ↗ |
| 19 | Daniel B. Asher | 1.49M | 1.60% | — | 1.49M | — | 1.49M | HC, IN | United States of America | 2021-01-29 | ↗ |
| 20 | Intracoastal Capital LLC | 1.49M | 1.60% | — | 1.49M | — | 1.49M | OO | United States of America | 2021-01-29 | ↗ |
| 21 | Mitchell P. Kopin | 1.49M | 1.60% | — | 1.49M | — | 1.49M | HC, IN | United States of America | 2021-01-29 | ↗ |
| 22 | Empery Tax Efficient II, LP | 880.0K | 2.90% | — | 880.0K | — | — | PN | Delaware | 2019-01-17 | ↗ |
| 23 | Empery Asset Master, Ltd. | 709.8K | 2.35% | — | 709.8K | — | — | PN | Cayman Islands | 2019-01-17 | ↗ |
| 24 | (2) | 606.8K | 7.00% | — | 606.8K | — | 75.0K | OO | — | 2024-09-11 | ↗ |
| 25 | Jeff Easton | 265.0K | 5.90% | 265.0K | — | 265.0K | — | IN | United States | 2024-03-06 | ↗ |
| 26 | Lind Global Fund II LP | 265.0K | 5.90% | 265.0K | — | 265.0K | — | PN | Delaware | 2024-03-06 | ↗ |
| 27 | Lind Global Partners II LLC | 265.0K | 5.90% | 265.0K | — | 265.0K | — | OO | Delaware | 2024-03-06 | ↗ |
| 28 | Altium Capital Management, LP | 250.0K | 4.00% | — | 250.0K | — | — | IA | United State of America | 2019-02-13 | ↗ |
| 29 | Altium Growth Fund, LP | 250.0K | 4.00% | — | 250.0K | — | — | PN | United States of America | 2019-02-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ADVISOR GROUP HOLDINGS, INC. | — -6.0 (-100.0%) | — -2.0 (-100.0%) | 0.00% -0.082 pp | 0.00% +0.000 pp | USD— | 11 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-12 | Telling Fred | Director | S-Sale | D | Common Stock | 210 | 0.94 | 198.37 | 948 | D | ↗ |
| 2025-12-11 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 125,000 | 0.93 | 116.3K | 125,000 | D | ↗ |
| 2025-12-11 | POPE CHARLES L | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 125,000 | 0.93 | 116.3K | 125,000 | D | ↗ |
| 2025-12-11 | KOSKI ROBERT C | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 125,000 | 0.93 | 116.3K | 125,000 | D | ↗ |
| 2025-12-11 | Huffman Janet | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.93 | 232.5K | 250,000 | D | ↗ |
| 2025-12-11 | Giordano Natasha | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 38,320 | 1.03 | 39.5K | 38,320 | D | ↗ |
| 2025-12-11 | GANDOLFO JOHN P | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 125,000 | 0.93 | 116.3K | 125,000 | D | ↗ |
| 2025-12-11 | DUNTON ALAN W | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 125,000 | 0.93 | 116.3K | 125,000 | D | ↗ |
| 2025-09-01 | Giordano Natasha | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-18 | Odyssey Health, Inc. | 10% Owner | S-Sale | D | Common Stock - OGEN | 5,044 | 4.26 | 21.5K | 0 | D | ↗ |
| 2025-06-17 | Odyssey Health, Inc. | 10% Owner | S-Sale | D | Common Stock - OGEN | 2,000 | 4.46 | 8.9K | 5,044 | D | ↗ |
| 2025-06-16 | Odyssey Health, Inc. | 10% Owner | S-Sale | D | Common Stock - OGEN | 5,000 | 4.45 | 22.3K | 7,044 | D | ↗ |
| 2025-06-13 | Odyssey Health, Inc. | 10% Owner | S-Sale | D | Common Stock - OGEN | 5,000 | 4.27 | 21.4K | 12,044 | D | ↗ |
| 2024-12-11 | KOSKI ROBERT C | Director | C-Conversion | A | Common Stock | 5,000 | 0.50 | 2.5K | 23,367 | I | ↗ |
| 2024-12-06 | Telling Fred | Director | S-Sale | D | Common Stock | 3,597 | 0.36 | 1.3K | 34,748 | D | ↗ |
| 2024-12-06 | DUNTON ALAN W | Director | S-Sale | D | Common Stock | 66 | 0.36 | 23.76 | 25,623 | D | ↗ |
| 2024-09-19 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 65,000 | 0.48 | 31.2K | 65,000 | D | ↗ |
| 2024-09-19 | REDMOND J MICHAEL | Officer | A-Award | A | Employee Option (Right to Buy) | 100,000 | 0.48 | 48.0K | 100,000 | D | ↗ |
| 2024-09-19 | POPE CHARLES L | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 100,000 | 0.48 | 48.0K | 100,000 | D | ↗ |
| 2024-09-19 | Murphy Kimberly M | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 27,083 | 0.48 | 13.0K | 27,083 | D | ↗ |
| 2024-09-19 | KOSKI ROBERT C | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 65,000 | 0.48 | 31.2K | 65,000 | D | ↗ |
| 2024-09-19 | Huffman Janet | Officer | A-Award | A | Employee Option (Right to Buy) | 80,000 | 0.48 | 38.4K | 80,000 | D | ↗ |
| 2024-09-19 | GANDOLFO JOHN P | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 45,000 | 0.48 | 21.6K | 45,000 | D | ↗ |
| 2024-09-19 | DUNTON ALAN W | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 65,000 | 0.48 | 31.2K | 65,000 | D | ↗ |
| 2024-09-19 | Cassidy Bruce A. Sr. | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 45,000 | 0.48 | 21.6K | 45,000 | D | ↗ |
| 2023-12-31 | KOSKI ROBERT C | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-28 | REDMOND J MICHAEL | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-28 | Odyssey Health, Inc. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 17,044 | D | ↗ |
| 2023-11-30 | Telling Fred | Director | S-Sale | D | Common Stock | 3,500 | 3.57 | 12.5K | 38,345 | — | ↗ |
| 2023-10-04 | GANDOLFO JOHN P | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 5,102 | 2.94 | 15.0K | 5,102 | — | ↗ |
| 2023-10-04 | Cassidy Bruce A. Sr. | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 5,102 | 2.94 | 15.0K | 5,102 | — | ↗ |
| 2023-08-08 | Telling Fred | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 41,845 | — | ↗ |
| 2023-08-08 | POPE CHARLES L | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,471 | — | ↗ |
| 2023-08-08 | Murphy Kimberly M | Director / Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2023-08-08 | KOSKI ROBERT C | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,689 | — | ↗ |
| 2023-08-08 | Huffman Janet | Officer | A-Award | A | Common Stock | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2023-08-08 | DUNTON ALAN W | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,689 | — | ↗ |
| 2023-03-07 | Huffman Janet | Officer | A-Award | A | Employee Option (Right to Buy) | 7,000 | 4.00 | 28.0K | 7,000 | — | ↗ |
| 2022-12-30 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 42,357 | 0.11 | 4.5K | 1,102,295 | — | ↗ |
| 2022-12-29 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 36,648 | 0.11 | 3.9K | 176,191 | — | ↗ |
| 2022-12-15 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 140,497 | 0.18 | 24.7K | 1,144,652 | — | ↗ |
| 2022-12-14 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 25,000 | 0.18 | 4.4K | 1,285,149 | — | ↗ |
| 2022-12-09 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 48,795 | 0.20 | 9.6K | 1,314,652 | — | ↗ |
| 2022-12-08 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 13,036 | 0.20 | 2.6K | 1,363,447 | — | ↗ |
| 2022-11-30 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 200,000 | 0.19 | 38.2K | 1,376,483 | — | ↗ |
| 2022-11-29 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 200,000 | 0.19 | 38.5K | 1,576,483 | — | ↗ |
| 2022-07-29 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 220,000 | 0.00 | — | 220,000 | — | ↗ |
| 2022-07-29 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-07-29 | POPE CHARLES L | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 220,000 | 0.00 | — | 220,000 | — | ↗ |
| 2022-07-29 | KOSKI ROBERT C | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 220,000 | 0.00 | — | 220,000 | — | ↗ |
| 2022-07-29 | DUNTON ALAN W | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 220,000 | 0.36 | 78.4K | 220,000 | — | ↗ |
| 2022-06-23 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-06-23 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 250,000 | 0.30 | 73.8K | 250,000 | — | ↗ |
| 2022-06-23 | Murphy Kimberly M | Officer | A-Award | A | Employee Option (Right to Buy) | 800,000 | 0.00 | — | 800,000 | — | ↗ |
| 2022-06-17 | Telling Fred | Director | P-Purchase | A | Common Stock | 10,084 | 0.29 | 2.9K | 1,010,000 | — | ↗ |
| 2022-05-23 | Telling Fred | Director | P-Purchase | A | Common Stock | 78,673 | 0.29 | 22.8K | 999,916 | — | ↗ |
| 2022-05-20 | Telling Fred | Director | P-Purchase | A | Common Stock | 65,718 | 0.28 | 18.6K | 917,743 | — | ↗ |
| 2022-05-19 | Telling Fred | Director | P-Purchase | A | Common Stock | 56,806 | 0.28 | 15.9K | 852,025 | — | ↗ |
| 2022-05-18 | Telling Fred | Director | P-Purchase | A | Common Stock | 15,303 | 0.26 | 4.0K | 795,219 | — | ↗ |
| 2022-03-30 | Telling Fred | Director | P-Purchase | A | Common Stock | 59,053 | 0.35 | 20.8K | 779,916 | — | ↗ |
| 2022-03-29 | Sullivan Michael O'Keefe | Officer | P-Purchase | A | Common Stock | 20,000 | 0.35 | 6.9K | 34,255 | — | ↗ |
| 2021-12-31 | KOSKI ROBERT C | Director | P-Purchase | A | Common Stock | 799,100 | 0.47 | 378.8K | 1,776,483 | — | ↗ |
| 2021-12-30 | KOSKI ROBERT C | Director | P-Purchase | A | Common Stock | 200,900 | 0.45 | 90.4K | 977,383 | — | ↗ |
| 2021-12-16 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 75,000 | 0.49 | 36.8K | 75,000 | — | ↗ |
| 2021-12-16 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 0.49 | 73.5K | 150,000 | — | ↗ |
| 2021-12-16 | POPE CHARLES L | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 75,000 | 0.49 | 36.8K | 75,000 | — | ↗ |
| 2021-12-16 | Murphy Kimberly M | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 75,000 | 0.49 | 36.8K | 75,000 | — | ↗ |
| 2021-12-16 | KOSKI ROBERT C | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 75,000 | 0.49 | 36.8K | 75,000 | — | ↗ |
| 2021-12-16 | DUNTON ALAN W | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 75,000 | 0.49 | 36.8K | 75,000 | — | ↗ |
| 2021-06-29 | Telling Fred | Director | M-Exempt | D | Non-Employee Director Option (Right to Buy) | 156,540 | 0.48 | 75.1K | 0 | — | ↗ |
| 2021-02-18 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 160,000 | 1.20 | 192.0K | 160,000 | — | ↗ |
| 2021-02-18 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 250,000 | 1.20 | 300.0K | 250,000 | — | ↗ |
| 2021-02-18 | POPE CHARLES L | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 160,000 | 1.20 | 192.0K | 160,000 | — | ↗ |
| 2021-02-18 | Murphy Kimberly M | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 160,000 | 1.20 | 192.0K | 160,000 | — | ↗ |
| 2021-02-18 | KOSKI ROBERT C | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 160,000 | 1.20 | 192.0K | 160,000 | — | ↗ |
| 2021-02-18 | Joslyn Alan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 400,000 | 1.20 | 480.0K | 400,000 | — | ↗ |
| 2021-02-18 | DUNTON ALAN W | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 160,000 | 1.20 | 192.0K | 160,000 | — | ↗ |
| 2021-01-14 | Hernandez Joseph | 10% Owner | S-Sale | D | Common Stock, $.001 par value | 870,854 | 0.98 | 856.5K | 0 | — | ↗ |
| 2021-01-13 | Hernandez Joseph | 10% Owner | S-Sale | D | Common Stock, $.001 par value | 257,510 | 0.80 | 206.0K | 870,854 | — | ↗ |
| 2021-01-12 | Hernandez Joseph | 10% Owner | S-Sale | D | Common Stock, $.001 par value | 629,707 | 0.73 | 460.2K | 1,128,364 | — | ↗ |
| 2021-01-11 | Hernandez Joseph | 10% Owner | S-Sale | D | Common Stock, $.001 par value | 441,929 | 0.77 | 340.7K | 1,758,071 | — | ↗ |
| 2021-01-07 | Hernandez Joseph | 10% Owner | S-Sale | D | Common Stock, $.001 par value | 323,997 | 0.84 | 272.2K | 2,200,000 | — | ↗ |
| 2021-01-06 | Hernandez Joseph | 10% Owner | S-Sale | D | Common Stock, $.001 par value | 1,000,000 | 0.60 | 600.0K | 2,523,997 | — | ↗ |
| 2021-01-05 | Hernandez Joseph | 10% Owner | S-Sale | D | Common Stock, $.001 par value | 500,000 | 0.58 | 290.2K | 3,523,997 | — | ↗ |
| 2021-01-04 | Hernandez Joseph | 10% Owner | S-Sale | D | Common Stock, $.001 par value | 176,003 | 0.52 | 91.5K | 4,023,997 | — | ↗ |
| 2021-01-02 | KOSKI ROBERT C | Director | G-Gift | D | Common Stock | 30,000 | 0.00 | — | 212,839 | — | ↗ |
| 2020-12-22 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 310,000 | 0.43 | 132.4K | 776,483 | — | ↗ |
| 2020-12-02 | Hernandez Joseph | 10% Owner | S-Sale | D | Common Stock, $.001 par value | 5,000,000 | 0.41 | 2.05M | 4,200,000 | — | ↗ |
| 2020-11-24 | Telling Fred | Director | P-Purchase | A | Common Stock | 100,000 | 0.37 | 37.0K | 439,538 | — | ↗ |
| 2020-05-14 | Telling Fred | Director | E-ExpireShort | A | Series 1 Common Stock Warrants (right to buy) | 50,000 | 0.75 | 37.5K | 0 | — | ↗ |
| 2020-05-14 | Joslyn Alan | Director / Officer | E-ExpireShort | A | Series 1 Common Stock Warrants (right to buy) | 33,333 | 0.75 | 25.0K | 0 | — | ↗ |
| 2020-05-01 | Murphy Kimberly M | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 138,664 | 0.43 | 60.0K | 138,664 | — | ↗ |
| 2020-05-01 | Hernandez Joseph | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 9,200,000 | — | ↗ |
| 2020-04-24 | KOSKI ROBERT C | Director | G-Gift | D | Common Stock | 35,000 | 0.00 | — | 242,839 | — | ↗ |
| 2020-02-05 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 156,540 | 0.48 | 75.1K | 156,540 | — | ↗ |
| 2020-02-05 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 250,000 | 0.48 | 120.0K | 250,000 | — | ↗ |
| 2020-02-05 | POPE CHARLES L | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 156,540 | 0.48 | 75.1K | 156,540 | — | ↗ |
| 2020-02-05 | KOSKI ROBERT C | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 156,540 | 0.48 | 75.1K | 156,540 | — | ↗ |
| 2020-02-05 | Joslyn Alan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 400,000 | 0.48 | 192.0K | 400,000 | — | ↗ |
| 2020-02-05 | DUNTON ALAN W | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 156,540 | 0.48 | 75.1K | 156,540 | — | ↗ |
| 2019-12-30 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 100,000 | 0.53 | 52.6K | 1,086,483 | — | ↗ |
| 2019-12-27 | KOSKI ROBERT C | Director | S-Sale | D | Common Stock | 100,000 | 0.52 | 51.7K | 1,186,483 | — | ↗ |
| 2019-08-09 | KOSKI THOMAS L | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-08-09 | KOSKI FAMILY LP | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-08-09 | KOSKI CHRISTINE L | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-08-09 | KOSKI BEVERLY | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-20 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 156,540 | 0.48 | 75.1K | 156,540 | — | ↗ |
| 2019-06-20 | POPE CHARLES L | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 156,540 | 0.48 | 75.1K | 156,540 | — | ↗ |
| 2019-06-20 | KOSKI ROBERT C | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 156,540 | 0.48 | 75.1K | 156,540 | — | ↗ |
| 2019-06-20 | DUNTON ALAN W | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 156,540 | 0.48 | 75.1K | 156,540 | — | ↗ |
| 2019-03-25 | Telling Fred | Director | P-Purchase | A | Common Stock | 100,000 | 0.75 | 75.0K | 339,538 | — | ↗ |
| 2019-03-25 | Joslyn Alan | Director / Officer | P-Purchase | A | Common Stock | 66,667 | 0.75 | 50.0K | 66,667 | — | ↗ |
| 2018-09-27 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 125,000 | 0.73 | 91.3K | 125,000 | — | ↗ |
| 2018-09-27 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 250,000 | 0.73 | 182.5K | 250,000 | — | ↗ |
| 2018-09-27 | POPE CHARLES L | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 125,000 | 0.73 | 91.3K | 125,000 | — | ↗ |
| 2018-09-27 | KOSKI FAMILY LP | 10% Owner | A-Award | A | Non-Employee Director Option (Right to Buy) | 125,000 | 0.73 | 91.3K | 125,000 | — | ↗ |
| 2018-09-27 | Joslyn Alan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 400,000 | 0.73 | 292.0K | 400,000 | — | ↗ |
| 2018-09-27 | DUNTON ALAN W | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 125,000 | 0.73 | 91.3K | 125,000 | — | ↗ |
| 2018-09-18 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 22,000 | 0.41 | 9.0K | 277,839 | — | ↗ |
| 2018-09-17 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 0.42 | 42.0K | 255,839 | — | ↗ |
| 2018-09-14 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 100 | 0.41 | 41.10 | 149,749 | — | ↗ |
| 2018-07-17 | Telling Fred | Director | P-Purchase | A | Common Stock Warrants (right to buy) | 100,000 | 1.00 | 100.0K | 100,000 | — | ↗ |
| 2018-07-17 | DUNTON ALAN W | Director | P-Purchase | A | Common Stock Warrants (right to buy) | 20,000 | 1.00 | 20.0K | 20,000 | — | ↗ |
| 2018-06-22 | Telling Fred | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 139,538 | — | ↗ |
| 2018-06-22 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 18,000 | 1.52 | 27.4K | 18,000 | — | ↗ |
| 2018-06-22 | POPE CHARLES L | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 28,108 | — | ↗ |
| 2018-06-22 | KOSKI FAMILY LP | Director / 10% Owner | A-Award | A | Common Stock | 4,000 | 0.00 | — | 108,789 | — | ↗ |
| 2018-06-22 | Joslyn Alan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 28,000 | 1.52 | 42.6K | 28,000 | — | ↗ |
| 2018-06-22 | DUNTON ALAN W | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 21,261 | — | ↗ |
| 2017-11-08 | KOSKI FAMILY LP | 10% Owner | J-Other | A | Common Stock Warrant | 2,419,355 | 0.31 | 750.0K | 5,419,355 | — | ↗ |
| 2017-06-22 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 140,000 | 0.37 | 51.8K | 140,000 | — | ↗ |
| 2017-06-22 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 175,000 | 0.37 | 64.8K | 175,000 | — | ↗ |
| 2017-06-22 | POPE CHARLES L | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 140,000 | 0.37 | 51.8K | 140,000 | — | ↗ |
| 2017-06-22 | KOSKI FAMILY LP | 10% Owner | A-Award | A | Non-Employee Director Option (Right to Buy) | 140,000 | 0.37 | 51.8K | 140,000 | — | ↗ |
| 2017-06-22 | Joslyn Alan | Director / Officer | A-Award | A | Employee Director Option (Right to Buy) | 140,000 | 0.37 | 51.8K | 140,000 | — | ↗ |
| 2017-06-22 | DUNTON ALAN W | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 140,000 | 0.37 | 51.8K | 140,000 | — | ↗ |
| 2017-02-09 | Telling Fred | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 1,355,354 | — | ↗ |
| 2017-02-09 | POPE CHARLES L | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 241,063 | — | ↗ |
| 2017-02-09 | KOSKI FAMILY LP | 10% Owner | A-Award | A | Common Stock | 40,000 | 0.00 | — | 1,047,878 | — | ↗ |
| 2017-02-09 | DUNTON ALAN W | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 172,588 | — | ↗ |
| 2016-06-30 | Telling Fred | Director | P-Purchase | A | Common Stock | 969,180 | 0.52 | 500.0K | 1,315,354 | — | ↗ |
| 2016-06-30 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 5,815,080 | 0.52 | 3.00M | 12,864,822 | — | ↗ |
| 2016-06-30 | KIRK RANDAL J | 10% Owner | P-Purchase | A | Common Stock | 2,261,419 | 0.52 | 1.17M | 14,481,089 | — | ↗ |
| 2016-06-24 | KOSKI FAMILY LP | 10% Owner | D-Return | D | Common Stock | 20,000 | 0.00 | — | 1,572,523 | — | ↗ |
| 2016-06-06 | Joslyn Alan | Director / Officer | A-Award | A | Employee Director Option (Right to Buy) | 300,000 | 0.55 | 165.0K | 300,000 | — | ↗ |
| 2016-02-16 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 80,000 | 0.84 | 67.2K | 80,000 | — | ↗ |
| 2016-02-16 | POPE CHARLES L | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 80,000 | 0.84 | 67.2K | 80,000 | — | ↗ |
| 2016-02-16 | KOSKI FAMILY LP | 10% Owner | A-Award | A | Non-Employee Director Option (Right to Buy) | 80,000 | 0.84 | 67.2K | 80,000 | — | ↗ |
| 2016-02-16 | DUNTON ALAN W | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 132,588 | — | ↗ |
| 2015-12-31 | KOSKI FAMILY LP | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 530,851 | — | ↗ |
| 2015-12-15 | DUNTON ALAN W | Director | G-Gift | D | Common Stock | 15,100 | 0.00 | — | 92,588 | — | ↗ |
| 2015-12-01 | KIRK RANDAL J | 10% Owner | C-Conversion | A | Common Stock | 3,381,004 | 1.50 | 5.07M | 12,219,670 | — | ↗ |
| 2015-03-16 | Telling Fred | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 80,000 | 1.32 | 105.6K | 80,000 | — | ↗ |
| 2015-03-16 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 1.32 | 264.0K | 200,000 | — | ↗ |
| 2015-03-16 | POPE CHARLES L | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 161,063 | — | ↗ |
| 2015-03-16 | KOSKI FAMILY LP | 10% Owner | A-Award | A | Non-Employee Director Option (Right to Buy) | 80,000 | 1.32 | 105.6K | 80,000 | — | ↗ |
| 2015-03-16 | DUNTON ALAN W | Director | A-Award | A | Non-Employee Director Option (Right to Buy) | 80,000 | 1.32 | 105.6K | 80,000 | — | ↗ |
| 2014-12-31 | DUNTON ALAN W | Director | — | D | Common Stock | 0 | 0.00 | — | 67,688 | — | ↗ |
| 2014-12-12 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 100 | 0.82 | 81.51 | 690,809 | — | ↗ |
| 2014-12-11 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 300 | 0.81 | 243.72 | 662,924 | — | ↗ |
| 2014-12-10 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 100 | 0.87 | 87.00 | 662,624 | — | ↗ |
| 2014-12-08 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 0.88 | 35.2K | 40,000 | — | ↗ |
| 2014-12-08 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 400 | 0.88 | 352.00 | 1,086,123 | — | ↗ |
| 2014-12-04 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 200 | 0.88 | 176.00 | 1,080,723 | — | ↗ |
| 2014-12-03 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 8,500 | 0.89 | 7.6K | 1,080,523 | — | ↗ |
| 2014-12-02 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 300 | 0.88 | 264.00 | 1,072,023 | — | ↗ |
| 2014-12-01 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 100 | 0.90 | 90.00 | 1,058,423 | — | ↗ |
| 2014-11-28 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 600 | 0.95 | 570.00 | 1,058,023 | — | ↗ |
| 2014-11-25 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 1,500 | 0.91 | 1.4K | 1,056,023 | — | ↗ |
| 2014-11-24 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 2,800 | 0.95 | 2.7K | 1,054,523 | — | ↗ |
| 2014-11-19 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 1,000 | 0.90 | 900.00 | 662,524 | — | ↗ |
| 2014-11-14 | Telling Fred | Director | P-Purchase | A | Common Stock | 100 | 0.95 | 94.95 | 246,076 | — | ↗ |
| 2014-11-13 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 5,800 | 0.85 | 4.9K | 637,978 | — | ↗ |
| 2014-11-12 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 200 | 0.87 | 173.94 | 623,178 | — | ↗ |
| 2014-11-11 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 5,900 | 0.85 | 5.0K | 609,778 | — | ↗ |
| 2014-11-10 | KOSKI FAMILY LP | 10% Owner | P-Purchase | A | Common Stock | 1,000 | 0.85 | 850.00 | 603,878 | — | ↗ |
| 2014-10-30 | Sullivan Michael O'Keefe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 25,000 | 0.86 | 21.5K | 25,000 | — | ↗ |
| 2014-08-13 | BONFIGLIO JOHN N | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 1.70 | 1.7K | 385,255 | — | ↗ |
| 2014-05-30 | Telling Fred | Director | A-Award | A | Common Stock | 10,000 | 2.05 | 20.5K | 239,174 | — | ↗ |
| 2014-05-30 | POPE CHARLES L | Director | A-Award | A | Common Stock | 10,000 | 2.05 | 20.5K | 121,063 | — | ↗ |
| 2014-05-30 | KOSKI FAMILY LP | 10% Owner | A-Award | A | Common Stock | 10,000 | 2.05 | 20.5K | 602,878 | — | ↗ |
| 2014-05-30 | DUNTON ALAN W | Director | A-Award | A | Common Stock | 10,000 | 2.05 | 20.5K | 67,888 | — | ↗ |
| 2014-03-28 | KOSKI FAMILY LP | 10% Owner | S-Sale | D | Common Stock | 200 | 3.05 | 610.00 | 1,041,723 | — | ↗ |
| 2014-03-26 | KOSKI FAMILY LP | 10% Owner | S-Sale | D | Common Stock | 100 | 3.08 | 308.00 | 1,046,153 | — | ↗ |
| 2014-03-26 | DUNTON ALAN W | Director | S-Sale | D | Common Stock | 5,000 | 3.05 | 15.3K | 57,888 | — | ↗ |
| 2014-03-25 | KOSKI FAMILY LP | 10% Owner | S-Sale | D | Common Stock | 2,400 | 3.05 | 7.3K | 1,046,253 | — | ↗ |
| 2014-03-25 | DUNTON ALAN W | Director | S-Sale | D | Common Stock | 7,000 | 3.00 | 21.0K | 62,688 | — | ↗ |
| 2014-03-20 | DUNTON ALAN W | Director | S-Sale | D | Common Stock | 2,000 | 3.03 | 6.1K | 69,688 | — | ↗ |
| 2014-03-14 | KOSKI FAMILY LP | 10% Owner | S-Sale | D | Common Stock | 309 | 3.15 | 973.35 | 1,048,653 | — | ↗ |
| 2014-03-13 | KOSKI FAMILY LP | 10% Owner | S-Sale | D | Common Stock | 100 | 3.23 | 323.00 | 1,056,462 | — | ↗ |
| 2014-03-12 | KOSKI FAMILY LP | 10% Owner | S-Sale | D | Common Stock | 817 | 3.12 | 2.5K | 1,056,662 | — | ↗ |
| 2014-03-11 | KOSKI FAMILY LP | 10% Owner | S-Sale | D | Common Stock | 2,000 | 3.10 | 6.2K | 1,057,479 | — | ↗ |
| 2014-03-11 | DUNTON ALAN W | Director | S-Sale | D | Common Stock | 1,500 | 3.40 | 5.1K | 71,688 | — | ↗ |
| 2014-03-10 | DUNTON ALAN W | Director | S-Sale | D | Common Stock | 875 | 3.32 | 2.9K | 73,188 | — | ↗ |
| 2014-02-11 | KOSKI FAMILY LP | 10% Owner | G-Gift | D | Common Stock | 450,000 | 0.00 | — | 519,666 | — | ↗ |
| 2014-01-21 | KOSKI FAMILY LP | 10% Owner | J-Other | D | Common Stock | 906,000 | 0.00 | — | 8,257,742 | — | ↗ |
| 2013-12-30 | DUNTON ALAN W | Director | S-Sale | D | Common Stock | 9,200 | 2.85 | 26.2K | 74,063 | — | ↗ |
| 2013-12-23 | DUNTON ALAN W | Director | S-Sale | D | Common Stock | 700 | 2.93 | 2.1K | 88,363 | — | ↗ |
| 2013-12-20 | DUNTON ALAN W | Director | S-Sale | D | Common Stock | 4,225 | 2.85 | 12.0K | 89,738 | — | ↗ |
| 2013-12-18 | KIRK RANDAL J | 10% Owner | C-Conversion | A | Common Stock | 698,241 | 2.82 | 1.97M | 8,838,666 | — | ↗ |
Executive team
Top executives
Shares Outstanding
4.34M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Joseph Redmond Former President and Interim Principal Executive Officer | 397.1K | — | — | 39.0K | — | 28.0K | 464.1K | 8.40% | ↗ |
| 2 | 2024 | Janet Huffman Chief Financial Officer, Interim Chief Executive Officer | 250.0K | 75.0K | — | 31.2K | — | 7.5K | 363.7K | 8.58% | ↗ |
| 3 | 2024 | Kimberly Murphy Former Chief Executive Officer and President | 53.8K | — | — | 10.6K | — | 216.6K | 280.9K | 3.76% | ↗ |
| 4 | 2023 | Kimberly Murphy Chief Executive Officer and President | 430.0K | 65.0K | 84.3K | — | — | 12.9K | 592.2K | 14.23% | ↗ |
| 5 | 2023 | Kimberly Murphy Former Chief Executive Officer and President | 430.0K | 65.0K | 84.3K | — | — | 12.9K | 592.2K | 14.23% | ↗ |
| 6 | 2023 | Janet Huffman Chief Financial Officer, Interim Chief Executive Officer | 208.3K | 130.0K | 50.6K | 27.4K | — | 4.1K | 420.3K | 18.54% | ↗ |
| 7 | 2023 | Joseph Redmond President and Interim Principal Executive Officer | — | — | — | 343.8K | — | — | 343.8K | 100.00% | ↗ |
| 8 | 2023 | Joseph Redmond Former President and Interim Principal Executive Officer | — | — | — | 343.8K | — | — | 343.8K | 100.00% | ↗ |
| 9 | 2023 | Janet Huffman Chief Financial Officer | 208.3K | 55.0K | 50.5K | — | — | 4.1K | 267.4K | 18.89% | ↗ |
| 10 | 2023 | Dr. Martin Handfield Senior Vice President Discovery Research | 214.1K | 41.9K | — | — | — | — | 256.0K | 0.00% | ↗ |
| 11 | 2022 | Kimberly Murphy Chief Executive Officer and President | 224.9K | 22.0K | — | 232.0K | — | 5.9K | 484.8K | 47.85% | ↗ |
| 12 | 2022 | Michael O. Sullivan Chief Financial Officer | 250.0K | 35.0K | — | 142.5K | — | 7.2K | 434.7K | 32.78% | ↗ |
| 13 | 2022 | Dr. Martin Handfield Senior Vice President Discovery Research Former Officer: | 223.2K | 34.9K | — | 35.0K | — | 6.7K | 299.8K | 11.68% | ↗ |
| 14 | 2022 | Dr. Martin Handfield Senior Vice President Discovery Research | 223.2K | 34.9K | — | 35.0K | — | 6.7K | 299.8K | 11.68% | ↗ |
| 15 | 2021 | Dr. Alan Joslyn President and Chief Executive Officer | 178.9K | 55.1K | — | 472.0K | — | 218.4K | 924.4K | 51.06% | ↗ |
| 16 | 2021 | Michael O. Sullivan Interim Principal Executive Officer and Chief Financial Officer | 238.3K | 70.0K | — | 367.0K | — | 7.1K | 682.4K | 53.78% | ↗ |
| 17 | 2021 | Michael O. Sullivan Chief Financial Officer | 238.3K | 70.0K | — | 367.0K | — | 7.1K | 682.4K | 53.78% | ↗ |
| 18 | 2021 | Dr. Martin Handfield Senior Vice President Discovery Research Former Officer: | 209.8K | 39.1K | — | 295.6K | — | 6.3K | 550.8K | 53.67% | ↗ |
| 19 | 2020 | Dr. Alan Joslyn President and Chief Executive Officer | 367.5K | 137.8K | — | 376.0K | — | 21.3K | 902.6K | 41.66% | ↗ |
| 20 | 2020 | Dr. Alan Joslyn (former President and Chief Executive Officer) | 367.5K | 137.8K | — | 376.0K | — | 21.3K | 902.6K | 41.66% | ↗ |
| 21 | 2020 | Michael O. Sullivan Interim Principal Executive Officer and Chief Financial Officer | 230.0K | 60.4K | — | 235.0K | — | 6.9K | 532.2K | 44.16% | ↗ |
| 22 | 2020 | Michael O. Sullivan Chief Financial Officer and Interim Principal Executive Officer | 230.0K | 60.4K | — | 235.0K | — | 6.9K | 532.2K | 44.16% | ↗ |
| 23 | 2020 | Dr. Martin Handfield Senior Vice President Discovery Research | 205.4K | 38.5K | — | 206.8K | — | 6.2K | 456.9K | 45.27% | ↗ |
| 24 | 2020 | Dr. Martin Handfield Senior Vice President Discovery Research Former Officer: | 205.4K | 38.5K | — | 206.8K | — | 6.2K | 456.9K | 45.27% | ↗ |
| 25 | 2019 | Dr. Alan Joslyn President and Chief Executive Officer | 367.5K | 87.3K | — | — | — | 33.6K | 488.4K | 0.00% | ↗ |
| 26 | 2019 | Dr. Alan Joslyn (former President and Chief Executive Officer) | 367.5K | 87.3K | — | — | — | 33.6K | 488.4K | 0.00% | ↗ |
| 27 | 2019 | Michael O. Sullivan Chief Financial Officer and Interim Principal Executive Officer | 230.0K | 76.5K | — | — | — | 6.9K | 313.3K | 0.00% | ↗ |
| 28 | 2019 | Michael O. Sullivan Chief Financial Officer | 230.0K | 76.5K | — | — | — | 6.9K | 313.3K | 0.00% | ↗ |
| 29 | 2019 | Dr. Martin Handfield Senior Vice President Discovery Research | 205.4K | 33.4K | — | — | — | 6.2K | 244.9K | 0.00% | ↗ |
| 30 | 2018 | Dr. Alan Joslyn President and Chief Executive Officer | 350.0K | 140.0K | — | 330.3K | — | 14.7K | 835.0K | 39.56% | ↗ |
| 31 | 2018 | Michael O. Sullivan Chief Financial Officer | 219.0K | 72.8K | — | 207.2K | — | 6.6K | 505.6K | 40.98% | ↗ |
| 32 | 2018 | Dr. Martin Handfield Senior Vice President Discovery Research | 195.6K | 39.1K | — | 182.6K | — | 5.9K | 423.1K | 43.14% | ↗ |
| 33 | 2017 | Dr. Alan Joslyn President and Chief Executive Officer | 350.0K | 105.0K | 2.5K | 93.6K | — | 10.5K | 561.6K | 17.11% | ↗ |
| 34 | 2017 | Michael O. Sullivan Chief Financial Officer | 219.0K | 53.7K | — | 85.0K | — | 6.6K | 364.2K | 23.33% | ↗ |
| 35 | 2017 | Michael O. Sullivan Chief Financial Officer Interim Principal Executive Officer | 219.0K | — | — | 85.0K | — | 6.6K | 310.5K | 27.36% | ↗ |
| 36 | 2017 | Dr. Martin Handfield Senior Vice President Discovery Research | 195.6K | 20.0K | — | 15.9K | — | 5.9K | 237.4K | 6.72% | ↗ |
| 37 | 2016 | Michael O. Sullivan Chief Financial Officer Interim Principal Executive Officer | 219.0K | 100.0K | — | 73.4K | — | 6.6K | 398.9K | 18.39% | ↗ |
| 38 | 2016 | Dr. Alan Joslyn President and Chief Executive Officer | 200.4K | 91.5K | 14.0K | 79.7K | — | 4.8K | 390.4K | 24.00% | ↗ |
| 39 | 2016 | Dr. Martin Handfield Senior Vice President of Discovery Research | 195.6K | 57.5K | — | 54.00 | — | 5.9K | 259.0K | 0.02% | ↗ |
| 40 | 2016 | Dr. Martin Handfield Senior Vice President Discovery Research | 195.6K | 57.5K | — | 54.00 | — | 5.9K | 259.0K | 0.02% | ↗ |
| 41 | 2015 | Dr. Martin Handfield Senior Vice President of Discovery Research Former Employee | 195.6K | 20.8K | — | 228.3K | — | 5.5K | 450.2K | 50.71% | ↗ |
| 42 | 2015 | Dr. Martin Handfield Senior Vice President of Discovery Research | 195.6K | 20.8K | — | 228.3K | — | 5.5K | 450.2K | 50.71% | ↗ |
| 43 | 2015 | Michael O. Sullivan Chief Financial Officer Interim Principal Executive Officer | 219.0K | 41.4K | — | 152.2K | — | 6.6K | 419.2K | 36.31% | ↗ |
| 44 | 2015 | Albert Fosmoe Senior Vice President of Operations/Product Development | 232.3K | 24.7K | — | 119.2K | — | — | 376.2K | 31.69% | ↗ |
| 45 | 2014 | Dr. John Bonfiglio Former Chief Executive Officer | 279.2K | 29.5K | — | 38.8K | — | 56.5K | 404.1K | 9.59% | ↗ |
| 46 | 2014 | Albert Fosmoe Senior Vice President of Operations/Product Development | 172.9K | 16.0K | — | 95.4K | — | 75.4K | 359.7K | 26.52% | ↗ |
| 47 | 2014 | Albert Fosmoe Senior Vice President of Operations/Product Development | 172.9K | 16.0K | — | 95.4K | — | 75.4K | 359.7K | 26.52% | ↗ |
| 48 | 2014 | Michael O. Sullivan Chief Financial Officer Interim Principal Executive Officer | 200.7K | 20.0K | — | 16.1K | — | 6.0K | 242.8K | 6.63% | ↗ |
| 49 | 2014 | Michael O. Sullivan Chief Financial Officer Interim Principal Executive Officer | 200.7K | 20.0K | — | 16.1K | — | 6.0K | 242.8K | 6.63% | ↗ |
| 50 | 2014 | Dr. Martin Handfield Senior Vice President of Discovery Research Former Employee | 180.6K | 13.5K | — | 8.1K | — | 5.4K | 207.6K | 3.89% | ↗ |
| 51 | 2014 | Dr. Martin Handfield Senior Vice President of Discovery Research | 180.6K | 13.5K | — | 8.1K | — | 5.4K | 207.6K | 3.89% | ↗ |
| 52 | 2013 | Dr. John Bonfiglio Former Chief Executive Officer | 282.9K | 28.0K | 1.15M | 92.6K | — | 8.4K | 1.56M | 79.50% | ↗ |
| 53 | 2013 | Dr. John Bonfiglio Chief Executive Officer Principal Executive Officer, (PEO) | 282.9K | 28.0K | 1.15M | 92.6K | — | 8.4K | 1.56M | 79.50% | ↗ |
| 54 | 2013 | Michael O. Sullivan Chief Financial Officer | 183.3K | 17.5K | 461.8K | 17.9K | — | — | 680.5K | 70.49% | ↗ |
| 55 | 2013 | Michael O. Sullivan Chief Financial Officer Interim Principal Executive Officer | 183.3K | 17.5K | 461.2K | 17.9K | — | — | 680.5K | 70.40% | ↗ |
| 56 | 2013 | Dr. Martin Handfield Vice President of Research And Development | 172.5K | 4.5K | 389.7K | 8.5K | — | 5.1K | 580.3K | 68.61% | ↗ |
| 57 | 2013 | Dr. Martin Handfield Senior Vice President of Discovery Research | 172.5K | 4.5K | 389.7K | 8.5K | — | 5.1K | 580.3K | 68.61% | ↗ |
| 58 | 2013 | Albert Fosmoe Senior Vice President of Operations/Product Development | — | — | — | — | — | 198.8K | 198.8K | 0.00% | ↗ |
| 59 | 2012 | Dr. John Bonfiglio Chief Executive Officer Principal Executive Officer, (PEO) | 280.0K | 70.0K | 290.3K | 92.6K | — | 8.4K | 741.3K | 51.65% | ↗ |
| 60 | 2012 | Michael O. Sullivan Chief Financial Officer | 162.9K | 5.0K | 175.4K | 33.8K | — | — | 377.1K | 55.47% | ↗ |
| 61 | 2012 | Dr. Martin Handfield Vice President of Research And Development | 171.0K | 5.0K | 95.4K | 29.4K | — | 5.1K | 305.9K | 40.79% | ↗ |
| 62 | 2011 | John N. Bonfiglio Ph.D. Chief Executive Officer | 168.7K | 16.3K | 43.5K | 421.0K | — | 4.6K | 654.1K | 71.02% | ↗ |
| 63 | 2011 | Brian J. Bohunicky Chief Financial Officer | 200.0K | — | 51.9K | 29.2K | — | 6.0K | 287.1K | 28.25% | ↗ |
| 64 | 2011 | Dr. Jeffrey D. Hillman CEO | 166.7K | — | 40.2K | — | — | 29.4K | 236.3K | 17.03% | ↗ |
| 65 | 2011 | Dr. Martin Handfield Vice President of Research and Development | 171.0K | — | 14.9K | 2.1K | — | 5.1K | 193.1K | 8.78% | ↗ |
| 66 | 2011 | Dr. Robert Zahradnik Vice President of Operations | 135.0K | — | 14.9K | 1.7K | — | 4.1K | 155.6K | 10.61% | ↗ |
| 67 | 2011 | David Hirsch Chief Executive Officer | 21.3K | — | — | — | — | 124.0K | 145.3K | 0.00% | ↗ |
| 68 | 2011 | Michael Sullivan Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 69 | 2010 | David Hirsch Chief Executive Officer | 225.0K | — | — | — | — | 6.8K | 231.8K | 0.00% | ↗ |
| 70 | 2010 | David Hirsch Chief Executive Officer | 225.0K | — | — | — | — | 6.8K | 231.8K | 0.00% | ↗ |
| 71 | 2010 | Brian J. Bohunicky Chief Financial Officer | 200.0K | — | — | — | — | 6.0K | 206.0K | 0.00% | ↗ |
| 72 | 2010 | Brian J. Bohunicky Chief Financial Officer and Principal Financial Officer | 200.0K | — | — | — | — | 6.0K | 206.0K | 0.00% | ↗ |
| 73 | 2010 | Dr. Jeffrey D. Hillman Chief Scientific Officer | 200.0K | — | — | — | — | 6.0K | 206.0K | 0.00% | ↗ |
| 74 | 2010 | Dr. Jeffrey D. Hillman CEO | 200.0K | — | — | — | — | 6.0K | 206.0K | 0.00% | ↗ |
| 75 | 2010 | Gerard “Gerry” V. David Executive Vice President Sales and Marketing | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 76 | 2010 | Dr. Martin Handfield Vice President of Research and Development | 171.0K | — | — | — | — | 5.1K | 176.1K | 0.00% | ↗ |
| 77 | 2010 | Dr. Martin Handfield Director of Research and Development | 171.0K | — | — | — | — | 5.1K | 176.1K | 0.00% | ↗ |
| 78 | 2010 | Dr. Robert Zahradnik Vice President of Operations | 135.0K | — | — | — | — | 4.1K | 139.1K | 0.00% | ↗ |
| 79 | 2010 | John N. Bonfiglio Ph.D. Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 80 | 2010 | Michael Sullivan Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 81 | 2010 | Dr. John Bonfiglio Chief Executive Officer and Principal Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 82 | 2009 | David Hirsch, Chief Executive Officer (CEO), President and Principal Executive Officer (“PEO”) | 214.6K | 100.0K | — | 413.2K | — | 9.4K | 737.2K | 56.05% | ↗ |
| 83 | 2009 | Dr. Jeffrey D. Hillman Chief Scientific Officer | 182.3K | — | — | 318.2K | — | 86.7K | 587.1K | 54.20% | ↗ |
| 84 | 2009 | Jeffrey D. Hillman Chief Scientific Officer | 182.3K | — | — | 318.2K | — | 86.7K | 587.1K | 54.20% | ↗ |
| 85 | 2009 | Gerard “Gerry” V. David Executive Vice President Sales and Marketing | 161.3K | — | — | 207.7K | — | — | 369.0K | 56.30% | ↗ |
| 86 | 2009 | Brian Bohunicky Chief Financial Officer And Principal Financial Officer (PEO) | 156.8K | — | — | 195.8K | — | 3.8K | 356.4K | 54.92% | ↗ |
| 87 | 2009 | Brian J. Bohunicky Chief Financial Officer and Principal Financial Officer | 156.8K | — | — | 195.8K | — | 3.8K | 356.4K | 54.92% | ↗ |
| 88 | 2009 | Dr. Martin Handfield Director of Research and Development | 158.8K | — | — | 136.3K | — | — | 295.1K | 46.18% | ↗ |
| 89 | 2009 | Stanley Stein Former President, CEO and PEO | 39.8K | — | — | — | — | 120.0K | 159.8K | 0.00% | ↗ |
| 90 | 2008 | Stanley Stein Former President, CEO and PEO | 145.8K | 75.0K | — | 54.1K | — | 40.0K | 314.8K | 17.17% | ↗ |
| 91 | 2008 | Robert T. Zahradnik Former Acting Chief Operating Officer | 80.0K | — | — | 64.5K | — | 89.8K | 234.3K | 27.53% | ↗ |
| 92 | 2008 | Jeffrey D. Hillman Chief Scientific Officer | 180.0K | — | — | 34.1K | — | 5.4K | 219.5K | 15.52% | ↗ |
| 93 | 2008 | David Hirsch, Chief Executive Officer (CEO), President and Principal Executive Officer (“PEO”) | 94.9K | 50.0K | — | 16.3K | — | 23.7K | 185.0K | 8.84% | ↗ |
| 94 | 2008 | David Hirsch, President and CEO and Principal Executive Officer (“PEO”) | 94.9K | 50.0K | — | 16.3K | — | 23.7K | 185.0K | 8.84% | ↗ |
| 95 | 2008 | Dotti Delfino, Former Chief Financial Officer and PFO | 61.7K | — | — | — | — | 50.0K | 111.7K | 0.00% | ↗ |
| 96 | 2008 | Ronald Evans, Former President, CEO and PEO | 20.2K | — | — | — | — | — | 20.2K | 0.00% | ↗ |
| 97 | 2008 | Brian Bohunicky Chief Financial Officer And Principal Financial Officer (PEO) | — | — | — | — | — | — | — | — | ↗ |
| 98 | 2007 | Robert T. Zahradnik Former CEO, President and Principal Executive Officer | 180.0K | — | — | 16.6K | — | 1.8K | 198.4K | 8.37% | ↗ |
| 99 | 2007 | Robert T. Zahradnik Former Acting Chief Operating Officer | 180.0K | — | — | 16.6K | — | 1.8K | 198.4K | 8.37% | ↗ |
| 100 | 2007 | Jeffrey D. Hillman Chief Scientific Officer | 180.0K | — | — | 8.0K | — | 1.5K | 189.5K | 4.22% | ↗ |
| 101 | 2007 | Jeffrey D. Hillman Chief Scientific Officer | 180.0K | — | — | 8.0K | — | 1.5K | 189.5K | 4.22% | ↗ |
| 102 | 2007 | Dotti Delfino, Former Chief Financial Officer and PFO | 84.4K | — | — | — | — | — | 84.4K | 0.00% | ↗ |
| 103 | 2007 | Stanley Stein Former President, CEO and PEO | — | — | — | — | — | — | — | — | ↗ |
| 104 | 2007 | Ronald Evans, Former President, CEO and PEO | — | — | — | — | — | — | — | — | ↗ |
| 105 | 2007 | David Hirsch, President and CEO and Principal Executive Officer (“PEO”) | — | — | — | — | — | — | — | — | ↗ |
| 106 | 2006 | Jeffrey D. Hillman Chief Scientific Officer | 180.0K | — | — | 2.5K | — | 1.8K | 184.3K | 1.38% | ↗ |
| 107 | 2006 | Robert T. Zahradnik Former CEO, President and Principal Executive Officer | 180.0K | — | — | 2.5K | — | 1.8K | 184.3K | 1.38% | ↗ |
| 108 | 2006 | Robert T. Zahradnik CEO, President, Secretary, Treasurer and Interim Financial Officer | 180.0K | — | — | 2.5K | — | 1.8K | 184.3K | 1.38% | ↗ |
| 109 | 2006 | Jeffrey D. Hillman Chief Scientific Officer | 180.0K | — | — | 2.5K | — | 1.8K | 184.3K | 1.38% | ↗ |
| 110 | 2006 | Paul A. Hassie, CFO, Secretary Treasurer | 55.1K | — | — | — | — | 546.00 | 55.6K | 0.00% | ↗ |
| 111 | 2005 | Jeffrey D. Hillman Chief Scientific Officer | 180.0K | — | — | — | — | 4.6K | 184.6K | 0.00% | ↗ |
| 112 | 2005 | Paul A. Hassie, CFO, Secretary Treasurer | 135.0K | — | — | — | — | 4.1K | 139.1K | 0.00% | ↗ |
| 113 | 2005 | Robert T. Zahradnik CEO, President, Secretary, Treasurer and Interim Financial Officer | 90.0K | — | — | — | — | 1.5K | 91.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Janet Huffman | Chief Executive Officer, President, Chief Financial Officer, Secretary & Treasurer | 407.5K | female |
| Charles L. Pope | Executive Chairman | 112.5K | male |
| James Kelly | Chief Medical Officer | — | — |
| William Franklin Peacock FACC | Chief Clinical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OGEN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
